A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma
Cabozantinib and pembrolizumab combination was explored in treatment-naive aCM. Toxicity was consistent with known profiles, but discontinuation rates were notable.
Authors
- Melanie Frees
- John Rieth (ORCID: https://orcid.org/0000-0002-4883-5301)
- Michele Freesmeier
- John Smestad (ORCID: https://orcid.org/0000-0001-7922-3319)
- Yousef Zakharia (ORCID: https://orcid.org/0000-0001-9480-2626)
- Asad Javed (ORCID: https://orcid.org/0000-0001-6527-8220)
- Douglas Laux (ORCID: https://orcid.org/0000-0001-6499-3708)
- Varun Monga (ORCID: https://orcid.org/0000-0002-1185-5448)
- Yejin Kim (ORCID: https://orcid.org/0000-0003-3900-6015)
- Sarah Mott
Institutions
- University of Iowa (US)
- University of California, San Francisco (US)
- University of Iowa Hospitals and Clinics (US)
- Mayo Clinic Hospital (US)
- University of Iowa Health Care (US)
- University of Iowa Holden Comprehensive Cancer Center
Publication Details
- Journal
- Cancer
- Published
- 2026-02-15
- DOI
- https://doi.org/10.1002/cncr.70326
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00